Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213744 · ClinicalTrials.gov registry record · Phase 2
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
A Phase 2 study, sponsored by Merrimack Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT02213744 is a Phase 2 study that was terminated before completion, run by Merrimack Pharmaceuticals. The registered enrollment target is 113 participants.
The verdict
NCT02213744, a Phase 2 study, was terminated before completion, sponsored by Merrimack Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients. Patients may not have been previously treated with an anthracycline in any setting. Patients must have received prior treatment with trastuzumab in any setting, have either progressed or are intolerant to ado-trastuzumab emtansine in the metastatic or locally advanced setting, have either progressed or are intolerant to pertuzumab in the metastatic or locally advanced setting or had disease recurrence within 12 months of pertuzumab treatment in the neoadjuvant or adjuvant setting.
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Gemcitabine
- DRUG Vinorelbine
- DRUG MM-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213744
The ClinicalTrials.gov registry entry for NCT02213744 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02213744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02213744 about?
NCT02213744 is a clinical study titled "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients". This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer ...
What is the current status of trial NCT02213744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2014-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02213744?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Gemcitabine (DRUG), Vinorelbine (DRUG), MM-302 (DRUG).
Who is sponsoring clinical trial NCT02213744?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.